Altay Therapeutics develops small-molecule drugs that target disease-causing transcription factors to treat chronic illnesses and cancers. The company uses a proprietary, integrated platform combining biochemical assays, next-generation computational biology, and chemoproteomics to discover novel inhibitors. Using that platform Altay discovered three first-in-class inhibitors, including one that targets DUX4, a key driver of facioscapulohumeral muscular dystrophy (FSHD). Altay was co-founded in 2019 by Dr. Ali Ozes and Dr. Osman Ozes and was accepted into Y Combinator. The company's stated vision is to be a leader in targeting disease-causing transcription factors and to extend patient lifespan via safer, more specific therapies. A US$3 million investment from SOLVE FSHD is intended to support identification and advancement of a DUX4 inhibitor toward clinical trials.

Total raised

$3M

Funding rounds

1

Latest round

Equity

Latest activity

Sep 2022